STOCK TITAN

Milestone Scient - MLSS STOCK NEWS

Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.

Comprehensive Overview

Milestone Scient (MLSS) is a pioneering company in the field of medical technology, specializing in computer-controlled local anesthetic delivery systems. With a commitment to enhancing patient comfort and clinical precision, the company has developed innovative systems that transform traditional injection techniques into a streamlined, virtually painless process. Operating across the dental and medical sectors, MLSS integrates advanced technology with ergonomic design to deliver solutions that cater to a broad spectrum of procedures.

Technology and Innovation

The core of MLSS's success lies in its proprietary technology, which focuses on computer-controlled delivery of local anesthetic agents. By automating the injection process, these systems ensure a controlled, gradual administration of anesthetic, markedly reducing discomfort and anxiety for patients. The technology uses precise algorithms and sensor-driven feedback to tailor the injection speed and pressure, providing a remarkable improvement over traditional manual methods.

Product Applications and Clinical Utility

MLSS's product portfolio is divided into two primary segments: Dental and Medical. In dentistry, the systems are marketed under trademarks that emphasize the technology's capacity for painless procedures, supporting a wide array of dental treatments ranging from routine cleanings and fillings to more complex procedures such as implants, root canals, and crowns. In the medical field, the applications extend to procedures in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, and orthopedics. These systems are engineered to ensure precision and reliability, making them suitable for diverse clinical applications.

Market Position and Global Reach

As an established player in the medical device segment, MLSS has solidified its position through a combination of technological innovation and strategic market penetration. The company’s systems are marketed and sold not only across the United States but also in over 25 countries, underscoring its global presence. MLSS's commitment to research and development and its focus on combining state-of-the-art technology with user-centric design have allowed it to navigate the competitive medtech landscape effectively. The company's ability to address clinical challenges through innovation has resonated with practitioners, helping to foster trust and reliability in its products.

Operational Excellence and Strategic Insights

MLSS operates with a dual-segment strategy focusing on both dental and medical markets, ensuring that its technological advancements impact a wide range of clinical practices. The systems, designed with precision and reliability, offer enhanced control during administration, making them indispensable tools in modern clinical settings. The company's strategic initiatives, including efforts to improve reimbursement strategies and expand its clinical adoption, are reflective of its robust operational framework. Moreover, MLSS maintains an emphasis on continuous innovation and partnerships which further bolster its position within the competitive landscape.

Why MLSS Stands Out

Two defining characteristics set Milestone Scient apart: its commitment to eliminating patient discomfort and its advanced, computer-controlled delivery technology. By converting complex manual procedures into automated precision processes, MLSS significantly reduces the challenges associated with traditional anesthetic administration. The integration of sophisticated control systems and real-time monitoring has not only refined the delivery process but also contributed to more consistent clinical outcomes.

Industry Keywords and Insights

Key industry terms such as computer-controlled injection, local anesthetic delivery, and painless injection technology are integral to understanding the value proposition of MLSS. These terms encapsulate the company’s strategic focus on blending technology with clinical expertise to provide superior, patient-centered solutions.

Conclusion

Milestone Scient represents a significant evolution in the realm of local anesthetic administration. By combining advanced technology with an acute understanding of clinical needs, the company has developed systems that offer both reliability and exceptional patient comfort. With robust global distribution and a comprehensive portfolio that addresses diverse clinical procedures, MLSS continues to set benchmarks in precision, efficiency, and patient care. The detailed approach to technological innovation and product efficacy makes MLSS a critical player in its industry, consistently enhancing the landscape of medical and dental care.

Rhea-AI Summary
Milestone Scientific Inc. has started selling CompuFlo Epidural disposables to The Pain and Rehabilitation Medical Group in California. Dr. Fabian Proano, the clinic's founder, conducted a successful evaluation of the technology, reporting 100% success in eight cases. The evaluation included Epidural Steroid Injection procedures in the lumbar, thoracic, and cervical thoracic junction of the spine. Dr. Proano has over 25 years of experience in interventional pain management and specializes in image-guided spinal and joint injections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Milestone Scientific Inc. (NYSE: MLSS) reported a decline in 2022 revenues of $8.8 million, down from $10.3 million in 2021, attributed mainly to a $1.4 million drop in sales from China and a decrease in domestic dental revenue. The company faced an operating loss of $8.8 million, compared to $7.4 million the previous year. Despite these challenges, Milestone made progress in its product rollout, particularly the CompuFlo® Epidural System, which received FDA clearance for thoracic applications, potentially enhancing its market penetration. The company also launched a new online store for dental products, aiming for improved customer relations and profitability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
Rhea-AI Summary

Milestone Scientific (NYSE:MLSS) will host a conference call on March 31, 2023, at 8:30 AM ET to discuss its 2022 financial results and corporate developments. U.S. callers can dial toll-free 888-506-0062, while international callers can reach the call at +1 973-528-0011, using access code 333430. An audio replay will be available until April 15, 2023, by calling 877-481-4010 for U.S. callers and +1 919-882-2331 for international. The company is known for its advanced computerized drug delivery instruments that facilitate painless injections, utilizing patented DPS Dynamic Pressure Sensing Technology® for improved patient safety and comfort.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
-
Rhea-AI Summary

Milestone Scientific Inc. (NYSE: MLSS), a leader in computerized drug delivery instruments, has begun sales of its CompuFlo® Epidural disposables at the University Pain and Spine Center, following a successful evaluation by Dr. Didier Demesmin. Dr. Demesmin endorses the CompuFlo Epidural Instrument for its objective measurement capabilities, enhancing procedure safety and speed. CEO Arjan Haverhals emphasized the importance of this adoption for establishing the CompuFlo Epidural System as the standard in epidural analgesia, boosted by recent FDA clearance for thoracic spine use, a significant step for market penetration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Milestone Scientific (NYSE:MLSS) has commenced sales of CompuFlo Epidural disposables in three Colorado pain management clinics. This follows successful evaluations by Dr. Brad Sisson, MD, who reported a 100% success rate in initial cases. The sales come shortly after receiving FDA clearance for thoracic use, signifying major advancements in patient safety and pain management efficiency. CEO Arjan Haverhals emphasized the technology's potential to improve outcomes and reduce risks in complex procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.92%
Tags
none
Rhea-AI Summary

Milestone Scientific Inc. (NYSE:MLSS) announced the registration of its CompuFlo® Epidural System with the U.S. Government's System for Award Management (SAM) on March 2, 2023. This registration is essential for bidding on government contracts, enabling the company to operate within federal agencies such as the Department of Defense and Veterans Affairs. CEO Arjan Haverhals highlighted the substantial market potential and the product's safety and efficiency benefits. The system is supported by clinical data showing reduced complication rates and potential cost savings for healthcare providers. Milestone also seeks Federal Supply Service approval for pricing uniformity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none

FAQ

What is the current stock price of Milestone Scient (MLSS)?

The current stock price of Milestone Scient (MLSS) is $0.9127 as of April 21, 2025.

What is the market cap of Milestone Scient (MLSS)?

The market cap of Milestone Scient (MLSS) is approximately 71.6M.

What does Milestone Scient specialize in?

Milestone Scient specializes in developing and manufacturing computer-controlled local anesthetic delivery systems for both dental and medical applications. Their systems are designed to provide painless, precise, and controlled delivery of local anesthetic.

How are the company’s products utilized in clinical settings?

The products are used to automate and control the injection of local anesthetics, enhancing patient comfort and clinical precision. They support a range of procedures in dentistry and medicine, from routine treatments to more complex surgeries.

In which markets does Milestone Scient operate?

Milestone Scient operates in both the dental and medical markets, offering solutions that cater to various clinical procedures. Their products are distributed domestically within the United States and internationally in over 25 countries.

What are the technological advantages of the company's systems?

The systems use computer-controlled algorithms and sensor feedback to deliver anesthetic agents in a precise, controlled manner. This technology reduces patient discomfort and improves the accuracy of injections compared to traditional manual techniques.

How does Milestone Scient ensure the efficacy of its delivery systems?

The company invests in continuous research and development to refine its technology. Their systems are rigorously tested and are designed to adapt to various clinical needs while maintaining high levels of precision and reliability.

How does the company differentiate itself from competitors?

MLSS differentiates itself through its proprietary, computer-controlled technology that offers improved patient comfort and clinical efficiency. Its dual-segment approach in dental and medical markets further enhances its competitive edge.

What clinical procedures benefit from the company’s technology?

Both routine dental procedures like cleanings and fillings and complex medical procedures in fields such as plastic surgery, dermatology, and orthopedics benefit from the precision and reliability of MLSS's anesthetic delivery systems.

What drives Milestone Scient's global market presence?

The company’s global presence is driven by its innovative technology, robust operational strategies, and the growing demand for precise, painless anesthetic delivery systems in various clinical settings. Its commitment to quality and strategic partnerships further supports its international expansion.
Milestone Scient

NYSE:MLSS

MLSS Rankings

MLSS Stock Data

71.64M
60.65M
22.9%
5.7%
0.11%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
LIVINGSTON